reports
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:20 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:20 am ET on Thursday, September 4, 2025 and will be posted on the Investors sectio...
Krystal Biotech Announces Update on Development Plans for Oncology Pro...
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance following inhaled or intratum...
Krystal Biotech Announces Second Quarter 2025 Financial and Operating ...
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. “With the approval of VYJUVEK in Europe and Japan, we ...
Krystal Biotech to Report Second Quarter 2025 Financial Results on Aug...
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For tho...
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of ...
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic medicine approved in Japan for the treatment of DEB PITTSBURGH, July 25, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that on July 24, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) ...
Jeune Announces Positive Results and Significant Aesthetic Improvement...
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally reverse the biology of ag...
Krystal Biotech Inc: 2 directors
Two Directors at Krystal Biotech Inc sold 35,873 shares at between 150.385USD and 150.392USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB...
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the tr...
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Tria...
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/25 at 8 months PITTSBURGH, June 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced t...
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthc...
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the I...
Krystal Biotech to Present at BofA Securities 2025 Health Care Confere...
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of...
Krystal Biotech Announces First Quarter 2025 Financial and Operating R...
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) today reported financ...
Krystal Biotech Announces European Commission Approval of VYJUVEK® for...
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-...
Krystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech to Present at Upcoming Scientific Conferences PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingInvited Oral Presentation Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary diseasePresenter: Trevor Parry, PhDDate and Time: May 17, 202...
Krystal Biotech to Report First Quarter 2025 Financial Results on May ...
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unabl...
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Tr...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa EC approval decision anticipated in second quarter of 2025 PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in...
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Confere...
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference PITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:50 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:50 pm ET on Tuesday, March 4, 2025 and wil...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SHAK SHAKE SHACK INC. CLASS A
SKT TANGER FACTORY OUTLET CENTERS INC.
RGR STURM RUGER & COMPANY INC.
POWI POWER INTEGRATIONS INC.
MD MEDNAX INC.
ICLR ICON PLC
HAS HASBRO INC.
CRAI CHARLES RIVER ASSOCIATES INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
AVNW AVIAT NETWORKS
LKO LAKES OIL N.L.
MX MAGNACHIP SEMICONDUCTOR CORP.
BELFB BEL FUSE INC. CL B
LAUR LAUREATE EDUCATION INC. CLASS A
PMTS CPI CARD GROUP
KRYS KRYSTAL BIOTECH INC
SWTX SPRINGWORKS THERAPEUTICS
CSTM CONSTELLIUM SE CLASS A
AM ANTERO MIDSTREAM CORP.
CADL CANDEL THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial ...
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, ending the quarter with $749.6 million in cash and investments PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter and full year ending Decem...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.